Key Ratio
USD
15.47
-0.83 (-5.1%)
NASDAQ:VRNA, VERONA PHARMA PLC
Industry: Biotechnology
End of Day: 2 October 2023 GMT-4
Income Statement Ratios
Fiscal
Gross Profit Margin
-
Net Profit Margin (Adj.)
-11359%
Return on Equity (Adj.)
-11.30%
Fiscal (USD)
Period End Date
Financials
Revenue
Gross Profit
EBITDA
Operating Profit
Net Income (To Shareholders)
Net Income (Adj.)
Ratios
Gross Profit Margin
EBITDA Margin
Operating Margin
Net Profit Margin (Adj.)
Return on Equity (Adj.)
Return on Equity (Adj.) 3Y
Return on Equity (Adj.) 5Y
Return on Assets (Adj.)
Return On Invested Capital (Adj.)
ROIIC 3Y
ROIIC 10Y
Degree Of Op. Leverage (EBIT)
Degree Of Op. Leverage (CFO)
Rule Of 40 (EBITDA)
Rule Of 40 (FCF)
Per Share
Revenue / Share
Operating Profit / Share
Diluted EPS
Diluted EPS (Adj.)
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
0.5
0.5
0.1
-
-67.3
-49.1
-66.1
-59.0
-68.7
-51.6
-42.8
-31.9
24.5%
-
-14,692%
-10,714%
-14,831%
-10,850%
-14,393%
-11,359%
-22.4%
-11.3%
-26.2%
-23.8%
-30.1%
-35.1%
-16.4%
-10.2%
-33.2%
-25.0%
-6.4%
-2.4%
-26.0%
-18.5%
-
-
-
-
-14,791
-10,813
-13,175
-11,654
0.006
0.006
-0.9
-0.7
-1.0
-0.6
-1.0
-0.7
In Millions except per share items.
Balance Sheet Ratios
Fiscal
Current Ratio
26.30x
Cash Ratio
24.70x
Total Debt to Equity Ratio
0.070x
Fiscal (USD)
Period End Date
Financials
Short Term Cash Investments
Total Assets
Total Debt
Total Liabilities
Total Equity
Ratios
Current Ratio
Cash Ratio
Total Debt to Equity Ratio
Net Debt (Cash) to Equity
Net Debt (Cash) to NTA
Cash Conversion Cycle
Avg Days Sales Out.
Avg Days Inventory Out.
Avg Days Payables Out.
Per Share
Total Assets / Share
Book Value/Share
Tangible Book Value / Share
Total Debt / Share
Cash / Share
Net Debt (Cash) / Share
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
227
270
259
303
10.6
20.4
29.0
30.8
230
273
12.8x
26.3x
12.0x
24.7x
0.05x
0.07x
-0.9x
-0.9x
-0.9x
-0.9x
-
-
-
114
-
-
6,832
6,832
3.4
3.8
3.0
3.4
3.0
3.4
0.1
0.3
3.0
3.4
-2.9
-3.2
In Millions except per share items.
Cash Flow Ratios
Fiscal (USD, MM)
Cash From Operations
-52.9
CAPEX
-
Free Cash Flow (FCF)
-52.9
Fiscal (USD)
Period End Date
Financials
CFO bef. W.C. Changes
Cash From Operations
CAPEX
Cash Flow From Investing
Cash Flow From Financing
Free Cash Flow (FCF)
Ratios
FCF Margin
Quality Of Earnings
Dividend Payout Ratio
Per Share
Cash From Operations / Share
Free Cash Flow / Share
Dividend / Share
Special Dividend / Share
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
-68.1
-51.0
-59.9
-52.9
-0.03
-
-0.03
-
140
211
-59.9
-52.9
-13,077%
-11,556%
-
-
-
-
-0.8
-0.7
-0.8
-0.7
-
-
-
-
In Millions except per share items.
Valuation Ratios
Fiscal
Price / Sales
3,668.00x
Price / Earnings (Adj.)
-49.80x
Price / Tangible Book
6.20x
Fiscal (USD)
Period End Date
Dividend Yield
Special Dividend Yield
Price / Sales
Price / Earnings (Adj.)
Price / Book
Price / Tangible Book
Price / CFO
Price / FCF
EV / EBIT
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
-
-
-
-
4,324x
3,668x
-40.4x
-49.8x
8.6x
6.2x
8.6x
6.2x
-33.1x
-31.7x
-33.1x
-31.7x
-21.2x
-25.1x
Other Ratios
Fiscal (USD)
Period End Date
Revenue Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Operating Profit Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Net Income (Adj.) Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Diluted (Adj.) EPS Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Cash From Operations Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Free Cash Flow Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
-98.9%
-98.9%
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Fiscal (USD)
Period End Date
Market Capitalization
Total Enterprise Value
Shares Outstanding
FY22
31 Dec 2022
LTM23 Q2
30 Jun 2023
1.6249b
1.7552b
1.399b
1.4843b
75.7876m
79.4584m
- Figures shown are in its reported currency unless stated otherwise.
- Net Income and its respective ratios are normalised for one-off items unless stated otherwise.
- PR = Press Release
- FYC = Financial Year Change
Make Smart Investment Choices